GlassScriptPhysician profile
Rae Lynn Benson
NPI 1427256734
$836.39
in general payments reported to CMS, 2019-2025
15 companies · $24.37 in 2025
The $24.37 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $370 · 2022: $156 · 2023: $144 · 2024: $142 · 2025: $24.37.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $310.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $310.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $171.18 | 2021-2023 | Saxenda, Wegovy |
| Lilly USA, LLC | $129.64 | 2021-2024 | Zepbound |
| Mayne Pharma Commercial LLC | $90.62 | 2021-2023 | |
| Bausch Health US, LLC | $76.37 | 2021-2023 | Aplenzin |
| Exact Sciences Corporation | $57.23 | 2023-2024 | Cologuard Collection Kit |
| Astellas Pharma US INC | $42.93 | 2022-2025 | Veozah |
| Acella Pharmaceuticals, LLC | $42.38 | 2024 | NP Thyroid 60 |
| Evofem Biosciences, INC. | $42.37 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $41.83 | 2021 | |
| Currax Pharmaceuticals LLC | $33.21 | 2022 | |
| Lupin INC. | $31.90 | 2021 | |
| Abbvie INC. | $29.42 | 2021 | |
| Azurity Pharmaceuticals, INC. | $19.20 | 2023 | Adthyza |
| Ibsa Pharma INC. | $14.70 | 2021 | |
| Davol INC. | $13.41 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rae Benson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.